OptimizeRx Corp. (OPRX)
Healthcare
- Fundamental
- 3
- Sentiment
- 3
- Technical
- 3
Do Nothing: liquidity hard block — avgDollarVolume20 ≈ $1.07M is below the $5.0M floor and the recent 3-session average ≈ $1.34M is below the $1.5M recent-liquidity floor; the tape is too thin to trade. Both entry types considered: a pullback/oversold limit is additionally countertrend (below a declining SMA200 with SMA50 < SMA200 and no momentum reclaim), and a breakout stop above the settled 7.63 swing high is structurally viable (stop 7.05, R/R ≈ 1.36) but uneconomic at this liquidity.
Company overview
OptimizeRx Corp. is a digital health company that provides electronic health record (EHR) workflow solutions. These solutions include financial messaging, patient education, and brand support for pharmaceutical companies to communicate with healthcare providers. Founded in 2006, the company is headquartered in Waltham, MA.
Fundamental
fairStrong liquidity and cash generation are offset by recent revenue declines and concentration risks.
Mixed fundamentals: strong liquidity and cash generation, but 2026 filings show a sharp revenue pullback and a return to small GAAP losses, with meaningful customer-concentration and internal-control risks. Valuation is reasonable on EV/Sales and EV/EBITDA and analyst targets imply upside, but the discounted-cash-flow outputs are not supportive; best treated as watchlist pending clearer top-line stabilization.
Sentiment
fairA new product integration and buy-side upgrade are countered by recent revenue declines.
Dominant near-term catalyst: OptimizeRx's 2026-09-22 product integration with The Trade Desk via OpenPath (announced confidence, not yet priced in), reinforced by a 2026-09-18 Buy upgrade. Sentiment delta is essentially flat (baseline ≈ −0.10 → scoring ≈ −0.02, determinate at low confidence on a thin degraded baseline) and the legal screen is clean; moderate red-flag cap applied for conflicting in-window signals (bullish new-catalyst flow vs. bearish post-Q2 digestion recaps).
Technical
fairTechnical indicators are mixed, but low trading volume prevents actionable setups.
Mixed technical picture. Close 7.48 sits above the rising SMA50 (7.27) but below SMA20 (7.66), EMA9/21 (7.52/7.55) and SMA200 (7.95); RSI14 49.51 neutral, Williams %R -58.26 mid-range, ADX14 17.58 weak/no trend; MACD line barely positive (0.03) but below its signal (0.09) with a negative histogram (-0.06). The 09-21 bounce (+3.4% off the 7.13 low) was constructive but participation is thin. The decisive disqualifier is liquidity: 20-day average dollar volume ~$1.07M vs the $5.0M floor, and the recent 3-session average ~$1.34M vs the $1.5M recent-liquidity floor — both hard blocks.
You’re looking at 2026-09-22 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

